Serum Anti-Müllerian Hormone: A Potential Biomarker for Polycystic Ovary Syndrome

This study evaluated serum anti-Müllerian hormone (AMH) as a biomarker for diagnosing polycystic ovary syndrome (PCOS) in 131 women with PCOS and 49 healthy controls in North India. It found significantly higher AMH levels in women with PCOS, particularly in phenotype A cases, with a median level of 8.5 ng/ml compared to 2.4 ng/ml in controls. The area under the ROC curve for AMH was 0.93, indicating high diagnostic accuracy. AMH was identified as the best predictor of PCOS, with a cut-off level of >4.1 ng/ml for total PCOS and 5.17 ng/ml for phenotype A cases. The study suggests AMH could be a reliable biomarker for PCOS diagnosis, offering an alternative to testosterone measurement, which requires more complex laboratory setups.